What changed in psilocybin law
Laws that changed, rules that moved, bills that advanced, and corrections to our own reading, newest first. Each entry is dated, and nothing is edited quietly.
228 dated entries across 91 records: 169 record updates, 10 regulatory actions, and 49 review confirmations. A correction stays on the page it corrected, saying what changed in our reading.
Oregon has opened a public comment period on new psilocybin rules that would change all licence fees and end reduced fees. Comments run from 1 to 21 September 2026, with public hearings on 15 and 16 September. The state gives rising costs and programme sustainability as the reason.
Australia's entry now names the provisions that actually limit prescribing, Appendix D clause 9 of the Poisons Standard and subsection 19(5) of the Therapeutic Goods Act, and records an application to allow psilocybine for existential distress at the end of life. A delegate decided on 29 May 2026 that the current scheduling remains appropriate, and a final decision is still to come. Psilocybin remains prescribable only by an authorised psychiatrist and only for treatment-resistant depression.
Denmark's entry pointed at an executive order that stopped being current in 2020. The order in force is now cited, and the listing itself is unchanged: mushrooms and their spores have been controlled since 2001.
North Macedonia's entry had no official source and applied one article's prison range to two different offenses. The gazette has now been read: the range belongs to the supply offense, the separate offense of enabling use carries one to five years, and a 2023 amendment says a person holding drugs for personal use is not to be punished.
Norway's entry said the 2025 drug reform was in effect. It is not: the Act has passed and been promulgated, but commencement is left to the King and has not been set, so nothing in it has started.
Track changes to psilocybin law.
Clinical trials, bills, and ballot measures across the world: one free email a month with what changed.
Every entry below started as one of these. The monthly email is the same log, before you have to come looking.
No spam. Never shared. Unsubscribe anytime. Privacy statement
The law won’t email you. We will.
California's 2025 research law is broader and shorter-lived than this entry said. AB 1103 speeds up state review of research using any Schedule I or Schedule II drug, psilocybin among them, rather than psychedelics specifically, and the fast-track expires on 1 January 2028.
Indiana's psilocybin research fund is funded at $300,000 a year, $600,000 over the two-year budget, and the money comes from the state's opioid settlement account rather than general tax revenue. The amount and its source are now recorded from the budget act itself.
Argentina's entry now cites the instrument that actually lists psilocybin. The statute it cited before, Law 23.737, never names the substance: it defines controlled drugs by reference to lists that the executive sets by decree, and the decree in force is Decree 122/2026.
Armenia's entry now cites the articles that actually carry the law: Article 396 of the 2021 Criminal Code for the criminal tier and Article 44.1 of the Code of Administrative Offences for the administrative one, replacing an insider-dealing article and an article repealed in 2004. The government decision that lists psilocin and psilocybin is cited for the first time, and the penalty range is restated from the statute.
Canada's entry now cites the regulation that actually carries the 1 October 2026 date, and corrects what it said would happen next. The exemption is being folded into new regulations rather than simply ending, so the Special Access Programme route is carried forward past that date.
Czechia's entry now cites a version of the law that can be read and checked, and records a limit it had missed: treatment is confined to psychiatric hospitals run directly by the Ministry of Health, and any other facility needs a permit.
Germany's entry was a year out of date. The regulator lists one psilocybin programme, running from 18 June 2026 to 17 June 2027 at a single institute in Mannheim for treatment-resistant depression, and the entry now says that instead of describing a national scheme.
Nepal's entry no longer says only that the law is evolving. It now states what the Narcotic Drugs (Control) Act actually lists, cites the government's own consolidated text and the drug regulator's import list, and explains that psilocybin's position rests on being left out of both rather than on any permission.
The Netherlands entry no longer says truffles are sold in licensed smart shops or that they were explicitly excluded from the 2008 ban. The Opium Act contains no smart-shop licence and never mentions truffles at all, so they fall outside it rather than being carved out of it.
Switzerland's entry now cites the schedule that actually names psilocybin, rather than resting only on the Narcotics Act article, which does not. Nothing about the law itself has changed.
Thailand's entry now carries the full set of penalties the Thai FDA publishes, including the fine attached to the five year term and the separate commercial and distribution band it had omitted. Nothing in Thai law has moved; the widely repeated 2026 reform claims trace only to content farms.
Arizona's trigger law was signed on 27 June 2025, not in April, and the provision that would allow psilocybin to be prescribed sits at a different section of the code than the entry named. Both are corrected from the enacted chapter text. The law itself is unchanged and still does nothing today.
Colorado's entry no longer calls healing centers 'in development': state-licensed centers have been operating since 2025.
Connecticut's entry now cites the text of the act itself rather than a bill tracking page that never mentioned psilocybin. Nothing about the law changed; the citation now supports what the entry says.
Louisiana's psychedelic-assisted therapy initiative is law and has been in force since 1 August 2026. The entry still described it as a bill awaiting the governor's signature.
Minnesota did enact psilocybin language in 2026 after all. It is not access: a cannabis act signed in May requires the state to publish a report by 15 January 2027 on how a psilocybin therapeutic use program could work. We had recorded that no psilocybin provision passed.
Montana's entry now says when its no-pending-legislation claim was last checked: the 1 Aug 2026 review. The legislature meets in odd-numbered years, so nothing can advance in regular session this year.
New Mexico's record now cites the rulemaking page rather than a programme page that has not been updated, and says plainly that the producer and laboratory rule is only proposed and the patient and practitioner rule was canceled and is to be rescheduled. The 2026 budget act, signed in March, is added: it funds the treatment equity fund and a university research programme and gives the Health Department another year to spend its 2025 start-up money.
Ohio's entry now dates its no-bills-with-movement claim to the 16 Aug 2026 review. The one cited proposal, listed as HB 249 of 2025, still shows no committee movement.
Oregon's entry now cites the session law rather than a bill overview page that did not carry the dates the entry published. The facts are the same; the citation now proves them.
Utah's entry overstated two things. The law allows a wider class of health systems than we described, following a 2026 renumbering, and we called the pilot operational when no state record shows that it is. The report the Legislature required by 1 July 2026 is registered as overdue and unfiled.
The British Virgin Islands entry now says plainly which part of its reading is ours. The statute lists psilocin; the view that unlisted fresh mushrooms leave a real ambiguity comes from comparing the territory's law to England before 2005, and no local instrument or court has said it. Confidence has been lowered accordingly.
Pakistan's entry quoted a Schedule-I heading that does not appear in the Act, and cut off its quotation of section 6 one clause early. Both are corrected against the Government of Pakistan's own consolidated text, which also carries a 2022 amendment the entry had never mentioned. Psilocybin's listing itself is confirmed.
Australia's entry now cites the national Poisons Standard rather than a Victorian state page. What the law says is unchanged.
Austria's entry was checked again against the statute itself and nothing had changed. The law names psilocybin mushrooms in its own words.
Belgium's entry pointed at the wrong article for the probation route open to people caught with drugs for their own use. It is article 9, not article 9bis, and the entry now says so. The penalties are unchanged.
Bolivia's entry now cites Bolivia's own official consolidated law rather than a third-party database, and names the 2017 law whose list actually covers psilocybin. A cultivation penalty the entry had cited rests on a cross-reference repealed in 2017 and has been removed. Psilocybin remains illegal.
Brazil's entry now cites the version of the controlled-substances list actually in force, and records that in August 2025 the Superior Court of Justice held that selling psilocybin mushrooms is drug trafficking even though the mushroom itself is not on the list. The status is unchanged.
Canada's entry now shows that the exemption connecting psilocybin to the Special Access Programme is revoked on 1 October 2026. The route is open until then.
Czechia's entry now cites the adopted regulation rather than the draft that was notified to the EU, and records which specialists may prescribe.
Denmark's entry said no bill was pending. A resolution proposal on psychedelics, B 5, had in fact been tabled and then lapsed when the session ended in March 2026, and the entry now records it. The list of banned substances also covers spores, which the entry had not mentioned.
Finland's entry had no primary source behind it. The Narcotics Act and the decree that lists psilocybin are now cited directly, and both say what the entry already said.
France's entry quoted a 500 euro fixed fine that was announced but never enacted. The statute sets 200 euros, reduced to 150 and raised to 450, and the entry now matches it.
Iceland's entry was checked again against the regulation that lists the substances. It bans psilocybin and psilocin outright, with no exception for freshly picked mushrooms, exactly as the entry says.
Jamaica's entry is flagged as not yet checked against the text of the Dangerous Drugs Act. What it says is unchanged; how confident the register is in it has been lowered.
Jamaica's entry has now been checked against the text of the Dangerous Drugs Act itself, which was the outstanding task. Neither the Act nor its regulations mentions psilocybin or mushrooms anywhere, so the status stands and confidence has been restored. The entry now says plainly that this is legality by omission, not an approved programme.
Lithuania's entry rested on a European agency summary and said the administrative route had been abolished in 2017. Using drugs without a prescription is still an administrative offence there; it is possession that is criminal. The entry now cites the Criminal Code and the substance list directly, and records that spores are covered.
Mexico's entry was checked line by line against the two statutes in force and everything it says about the law holds. One correction: a Senate initiative it described was presented in 2023, not 2024, and the entry no longer claims to know whether it is still alive.
The Netherlands entry was checked again against a newer version of the Opium Act. Mushrooms are still banned and truffles still are not in the Act at all, which is why they remain lawful. Two amendments this year touched other articles.
New Zealand's entry is re-verified against Medsafe's own guidance and two government releases, which date the prescribing pathway to June and July 2025 and confirm that psilocybin remains an unapproved medicine.
North Macedonia's entry is re-checked with no change found. The contradiction between how possession is written and how it is prosecuted stands, and we still have no official text of the Criminal Code to check either against.
Norway's entry described the 2025 drug reform as an agreement between parties. It had already passed the Storting and been promulgated in June 2025, and it is waiting on the King to bring it into force. It keeps the ban in place.
Peru's entry cited a version of the penal code article that had been replaced twice since. The current text is now cited from the official gazette. The list of drugs with a personal-use exemption still does not include psilocybin, so the status is unchanged.
Portugal's entry pointed at a dead source. The law itself has now been read from the official gazette, which confirms the 2001 start date and that cultivation is still a crime. The entry also now says plainly that this is a general all-drug law that never mentions psilocybin.
Sweden's entry was checked again against the statute and against a search of the Riksdag's own document service. The law is unchanged and nothing new has been put before parliament.
Switzerland's entry now reports 686 exceptional authorisations for 2024, 322 of them for psilocybin, citing the Federal Office of Public Health's own figures. It no longer describes these as patients: an authorisation runs about twelve months, covers several treatments and includes continuations of an existing therapy.
The United Kingdom entry was checked again against the Act, the regulations and the ACMD's own 2026 work programme. Psilocybin remains Class A and Schedule 1, and the review the government commissioned in 2025 has not reported.
Uruguay's entry credited the wrong law with the current wording of the drug-possession article; it was last rewritten in 2020, not 1998. The entry now also records the penalty range and notes that the article's only quantity limit applies to marijuana. The status is unchanged.
Arizona's pending-bill list named two bills that turned out to be about voter registration and residential property. Corrected against the legislature's own bill texts. The law itself is unchanged.
Connecticut's expanded pilot program took effect on 1 July 2026, not on the June signing date the entry previously showed. Corrected from the text of the act.
Checked against the enrolled text of the 2025 act. Florida's spore offence and its penalty are as recorded.
Indiana's research fund was paid for by the biennial state budget, not by the standalone bill the entry credited, and the fund now covers ibogaine as well as psilocybin. Corrected from the legislature's own records.
Maine's entry cited the wrong bill paper in the wrong Legislature, and still listed a dead bill as pending. Both fixed, and the law that actually prohibits possession is now named.
A note in Michigan's entry described an old decriminalization bill as an Oregon-style licensing bill and put it in the wrong session. Corrected against the legislature's record.
Mississippi's entry no longer lists the state's 2026 ibogaine research law as pending. It was signed in March 2026 and takes effect on 1 July 2026, and no psilocybin measure is pending.
Missouri's entry now says plainly what happened to the psilocybin study bill. It passed the House in April 2026, sat on the Senate's informal calendar from 7 May, and was never truly agreed before the session ended.
Nevada's entry was checked again on 16 August 2026. The state health department's own page confirms the 2023 working group is a study body. The legislature's website could not be reached, so the bill history is queued for a manual check.
New Hampshire's entry no longer lists HB 1772 as pending. It became law in 2026 as Chapter 333, it covers prescribing ibogaine for investigational use, and no psilocybin measure was enacted. Psilocybin is still a controlled drug in New Hampshire.
New Jersey's entry was checked again on 16 August 2026 and nothing changed. The legislature's website could not be reached, so the pilot programme's paperwork is queued for a manual check.
New York's entry was re-checked against the Senate's own bill pages on 16 August 2026. All four access bills are still in committee without a vote; one of them was amended in May 2026.
North Carolina's entry was checked again on 16 August 2026. The legislature's website blocks our requests, so the record could not be re-read and nothing was changed.
Ohio's entry was reviewed on 16 August 2026 without being re-checked against an Ohio government source, because Ohio's own statute and legislature websites could not be reached. Nothing was changed.
Texas's entry no longer carries an effective date. Texas has no psilocybin access law, so there is no date to give; the prohibition and the ibogaine research programme are unchanged.
Checked against the D.C. Council's own record of the law. Nothing has changed since it took effect in March 2021.
The British Virgin Islands entry pointed at the wrong schedule. The controlled-drug list is Schedule 2, and psilocin sits in its Class A part. The statute was read this time from the government's own live copy.
Poland's entry said the 2005 drug Act lists psilocybin. The Act's annexes have been repealed and the list now lives in a health ministry regulation, which the entry now cites. A separate amendment to that Act was signed in July 2026; it deals with treatment and procedure and leaves the possession offence and the substance lists alone.
Greece's entry named a drug code that was repealed in 2013. The operative law is Law 4139/2013, and the entry now cites it, along with the schedule that still names psilocybin and psilocin. Nothing about the legal status changed.
Canada's record said there were no bills before Parliament. There is one: C-286, a private member's bill introduced on 16 June 2026 that would allow psilocin and psilocybin to be used for medical treatment. It is not scheduled for debate, and the entry now says so.
California's record now lists SB 1224, the Emerging Therapies Research Partnership Act, which names psilocybin among the emerging therapies a state research fund would support in federally registered trials, with a veterans focus. The bill was held in the Assembly Appropriations suspense file on 13 Aug 2026.
Colorado's Natural Medicine Division put an emergency fee schedule for the regulated program into effect on 12 Aug 2026, with permanent rulemaking announced for later this year. The legal status of psilocybin in Colorado is unchanged.
Colombia's entry now cites the Constitutional Court's 1994 judgment directly and dates it 5 May 1994. The rewritten summary explains that no statutory quantity covers psilocybin and that police fines for personal-dose possession ended in December 2023.
Costa Rica's entry now cites Ley 8204 itself and dates its effect to 11 January 2002. The rewritten summary explains that the line between lawful possession and trafficking is a purpose test decided case by case rather than a quantity threshold.
Italy's entry now cites the consolidated Testo Unico directly. The summary lists what article 75 actually reaches and what it suspends, and treats quantity as a circumstance courts weigh rather than a line that decides the case.
Slovenia's entry now cites the classification decree annex directly and corrects the penalty description: a fine and up to thirty days, five for a small quantity, with articles 186 and 187 stated separately.
Spain's entry no longer calls small quantities legal. It describes the public-place administrative fine under Ley Organica 4/2015 and keeps personal consumption outside the criminal code, now citing the consolidated Penal Code as well.
This entry now carries much lower confidence. The licence scheme it describes comes from company announcements, and no government source for it has been found.
Australia's entry no longer calls the country the first to regulate psilocybin. It now says what the rule does instead: an authorised psychiatrist may prescribe it for treatment-resistant depression.
Germany's entry now describes how its compassionate use programme actually works. A sponsor notifies the regulator, which confirms the notification rather than granting an approval, and the confirmation has to be renewed each year.
The Bahamas is now recorded as illegal. A 2024 government order brought psilocybine under the Dangerous Drugs Act, and our earlier reading came from a 2017 version of the Act that predates it.
Canada's record now carries a date it was missing: the exemption that links psilocybin to the Special Access Program is revoked on October 1, 2026, when new regulations take effect.
Czechia's record drops an unsupported claim to be Europe's first such framework, and now states the three conditions the regulation actually names.
Maryland's record now explains something it never said: the state's drug law does not govern the clinical trials that run there. Those answer to federal regulators.
Northampton's date moves from March 18 to April 1, 2021. The city council gave the resolution a first reading in March and adopted it on the second reading two weeks later. Somerville's January 14, 2021 date and Cambridge's February 3, 2021 date were checked against city records and are unchanged. All eight Massachusetts municipal dates now come from municipal records.
Argentina's drug statute still criminalizes possession while courts apply the 2009 personal-use doctrine case by case. Nothing is pending, and the record now cites the law itself.
Alaska's psychedelics ballot initiative is listed as active by the Division of Elections, with petition booklets circulating and a September 2026 filing deadline. The record previously called it failed.
Colorado now lists 47 licensed healing centers as of July 31, 2026, per the state's Natural Medicine Division.
Georgia's veterans psychedelic pilot bill died at adjournment, and a bill number long recorded beside it turned out to be a court-fee act. Nothing is pending; the state's two 2026 psychedelic laws stand.
Hawaii's bill to create a psychedelics study task force died in conference committee at the end of the 2026 session. Nothing is pending.
Illinois's verification marker now reflects the July 2026 re-review, which confirmed the record against the legislature's own status pages.
Iowa's medical psilocybin bill died on the Senate calendar two days before adjournment, after passing the House 84 to 6. Nothing is pending.
Kansas's FDA-trigger psilocybin bill died on the House calendar on Turnaround Day in February, and the legislature has adjourned. Nothing is pending.
Kentucky's 2026 session ended with no psilocybin bill. Nothing is pending.
Maryland's ibogaine research bills died at adjournment and nothing is pending. The state's psychedelics task force now runs through 2027, with a report due this October.
Eight Massachusetts cities and towns have adopted resolutions making enforcement of psilocybin laws a low local priority, three more than this record named. Salem's is dated June 8, 2023, when the City Council adopted a revised resolution after the Acting Mayor vetoed the original.
Montana still lists psilocybin in Schedule I. The legislature does not meet in regular session this year and nothing is pending.
Rhode Island's record now lists H 7925 as pending. The committee's own 2026 agendas show it was never scheduled for a hearing.
Virginia's trigger laws are now recorded as signed on April 6, 2026, per the legislature's own bill histories.
An Irish Seanad bill to decriminalise personal drug possession is at committee stage, and the record now names it. Psilocybin's controlled status is unchanged.
Estonia's recorded maximum fine for small-quantity possession is corrected to 300 fine units, and the record now cites the law itself.
Latvia's record now cites the exact law that makes small-amount possession an administrative offence. The status itself is unchanged.
Ukraine's record now reflects the 2023 reform: first-time possession above the small-amount threshold is punished without imprisonment. Small amounts stay an administrative offence.
Illinois still lists psilocybin as a Schedule I controlled substance. A Senate-passed advisory board bill remains stalled in the House.
The Massachusetts House voted 148 to 2 for a bill carrying a supervised psilocybin pilot. The Senate removed the pilot and the bill is now in conference.
Minnesota's record now lists three more psilocybin bills from the 2026 session. None passed, and the session adjourned in May 2026.
New Mexico's record no longer says $4 million was appropriated for the medical psilocybin program. The enacted act creates two funds that the legislature funds separately.
Rhode Island's pending bill list is cleared. H 7756 was withdrawn in April 2026, and a parallel bill introduced in February 2026 is recorded in the summary.
South Dakota's record no longer lists its enacted trigger law as pending. The law turns on FDA approval alone, not on any DEA action.
Virginia's psilocybin trigger laws are recorded as chapters 305 and 306 and have been in force since July 1, 2026. The trigger has not fired and psilocybin stays in Schedule I.
Washington's record now cites the 2023 session law itself. That act was a partial veto which struck the advisory board and the health department's rulemaking authority, and it took effect July 23, 2023.
Oregon is taking public comment on a petition to change the rule that sets how facilitator training courses are approved. Comments close 29 Aug 2026. The program itself is unchanged.
West Virginia's pending bill list is cleared. HB 4626 was vetoed and SB 906 is already enacted as the state's trigger law.
Armenia is now recorded as mixed. Small amounts are an administrative offense, while larger quantities remain a criminal offense.
Croatia's record now cites the official gazette. The decriminalized status is unchanged.
Oregon's pending bill list is cleared. HB 4040 is enacted and HB 4110 died in committee.
The FDA issued final guidance on how psychedelic drugs should be studied in clinical trials, replacing the draft it published in 2023. Guidance sets out what the agency expects; it does not carry the force of law (91 FR 43101).
The FDA set a public hearing on the possible future medical use of psychedelic drugs for 14 Sep 2026 and began taking written comments. Anyone wanting to attend or ask to speak must register by 21 Aug 2026 (91 FR 43095).
The Health Resources and Services Administration asked the public how psychedelic treatments should be staffed and delivered in outpatient clinics if any are ever approved, with comments closing 13 Aug 2026 (91 FR 43103).
The supporting citation for HB 2218 moves from a bill-tracking site to the Kansas Legislature's own note on the bill. We use trackers to find bills and official pages to say what they contain.
The entry now cites Montana's own Schedule I listing at section 50-32-222 rather than a bill-tracking page. State records confirm LC 1208 was the draft number for HB 955.
The entry had linked to a bill-tracking site. It now links to the Rhode Island General Assembly's own text of H 7756. Trackers are useful for finding a bill; the legislature is what we cite.
Oregon's psilocybin program laid out its 2026 rule changes: proposed rules publish 1 Sep 2026 and restructure all fees, including ending reduced fees. Public comment runs 1 to 21 Sep, with hearings 15 and 16 Sep. The program's legal status is unchanged.
Louisiana's psychedelic-assisted therapy initiative became law as Act 956. It takes effect August 1, 2026.
Poland's illegal status was confirmed against the full text of the 2005 drug Act. Article 62a lets prosecutors drop small-amount cases at their discretion, which is not decriminalization. A widely repeated claim that Poland passed a medical psilocybin reform in 2026 was checked and rejected; it appears to confuse Poland with Czechia.
Ireland's entry had cited a hemp order by mistake. It now cites the Misuse of Drugs Regulations 2017 and the 2006 order that brought psilocybin mushrooms within the law. Possession for personal use is a criminal offence, as recorded.
Greece was confirmed illegal, and a widely repeated online claim that the country runs a state medical prescribing program was checked and found to have nothing behind it.
Pakistan's listing was checked against the government's own text of the Control of Narcotic Substances Act. Schedule-I names psilocybine at entry 69, and section 6 permits only medical, scientific or industrial use.
Argentina was moved out of the decriminalized column. The statute still makes possession a crime, and the Supreme Court's 2009 ruling is applied case by case rather than across the board.
An early review recorded small-amount possession as an administrative offense, drawing on a campaigners' map rather than Armenia's own text. The criminal code could not be read at the time, so no effective date was set.
Checked, with no change found. A 2026 consultation may widen who is allowed to prescribe under Australia's Authorised Prescriber scheme, but psilocybine's Schedule 8 listing for treatment-resistant depression is what it has been since 2023.
Austria was filed as having decriminalized possession. It has not: possession is a criminal offense that prosecutors may divert into probation and treatment, and the status was corrected to illegal.
A full-text check of the Bahamas statute portal found psilocybin absent from the Dangerous Drugs Act, though LSD was listed there, so nothing in the entry changed at this review.
Belgium was listed as decriminalized and it is not. The 1921 law itself puts possession at three months to five years in prison, so the status was corrected to illegal.
Bolivia had been recorded as legal on the strength of an entry that was actually about ayahuasca. Ley 1008 lists psilocybin, and the status was corrected to illegal.
Brazil had been recorded as legal. It is not. Psilocybin and psilocin are prohibited under Lista F2 of Portaria 344/1998, the mushrooms themselves are unlisted, and the courts are split on what that means, so the status is corrected to mixed.
Canada's medical access route was checked and left as it stood. Two things had moved around it during 2025: approvals slowed under a new government, and the Federal Court of Appeal ruled in June 2025 on exemptions for practitioners training to deliver the therapy.
Chile's decriminalized status was confirmed against the official text of Ley 20.000. Personal use stays outside the trafficking offense and nothing in the entry changed.
Colombia's status was confirmed, and the entry gained the three instruments that actually produce it: the 1994 judgment, the 2012 judgment that kept the trafficking offense alive, and the December 2023 repeal of the police fines for personal-dose possession.
Costa Rica's decriminalized status was confirmed: Ley 8204 attaches no penalty to personal consumption. The entry gained the caveat that the statute sets no quantity threshold at all.
Croatia's decriminalization dates from when the amendments took effect on 1 January 2013, not from the December day parliament passed them. The date shown is corrected.
Czechia's prescribing scheme was confirmed in force from 1 Jan 2026, and the entry now cites the act and the December 2025 decree that create it. The first treatments were expected in the second half of 2026.
Denmark had been recorded as mixed, which overstated the position. Possession is criminal, the only exceptions are for research, and no medical program exists, so the status moves to illegal.
Ecuador's entry rested on quantity tables that had already been repealed in November 2023. Consumption is still constitutionally protected, but with no threshold left, possession is judged case by case, so the status moved to mixed.
Estonia's misdemeanor regime was confirmed, and a draft Penal Code amendment that would treat dependent users differently from dealers was added to the entry.
Finland had been marked mixed, on the strength of an unsettled question about ayahuasca. That says nothing about psilocybin, which is a criminal narcotics offense in Finland, so the status is corrected to illegal.
France was filed as having decriminalized drug use. The fine police can issue on the spot is a criminal penalty for a criminal offense, and a law of June 2025 hardened enforcement, so the status was corrected to illegal.
Germany's compassionate use program was confirmed active and unchanged, though the regulator's psilocybin-specific listing could not be read directly at this review.
Iceland had been recorded as mixed on the theory that freshly picked mushrooms fell outside the ban. Regulation 233/2001 draws no such line, so the status was corrected to illegal.
Israel's entry claimed a medical route that does not exist. Psilocybin is approved for no indication there and reachable only through clinical trials, so the status was corrected to illegal.
Italy's decriminalized status was confirmed: personal possession is an administrative offense under article 75 of DPR 309/1990, not a crime.
Jamaica's status held. The health ministry's 2024 warning about psilocybin products, and public calls to amend the Dangerous Drugs Act, changed no law, and a weak source was dropped from the entry.
Latvia's decriminalized status was confirmed. Small-amount possession draws a warning or a fine of up to EUR 280, while larger quantities stay criminal.
Lithuania had been listed as decriminalized. Since 2017 possessing even a small quantity has been a criminal matter under Article 259(2) of the Criminal Code, so the status is corrected to illegal.
Mexico's small-quantity rule works off a dose table that leaves psilocybin out. Possession still carries four to seven and a half years, with one narrow exemption for indigenous and Afro-Mexican ceremonies, so the status moved from decriminalized to illegal.
Psilocybin is not named in Nepal's Narcotic Drugs (Control) Act, 2033 (1976). That leaves it unscheduled rather than permitted, and the entry stays recorded as mixed.
The Netherlands entry now points at the Dutch legal texts themselves, after the government link it had been citing stopped working. Truffles are unaffected, and a viral claim about a January 2026 mushroom fine was checked and found to be false.
New Zealand had been recorded as decriminalized, which was wrong: psilocybin is a Class A drug. The status was corrected to medical because Medsafe began approving individual prescribers in 2025.
North Macedonia had been listed as decriminalized. Drug use is a fine-only misdemeanor there, but possession is treated as criminal and is prosecuted in practice, and the available sources contradict each other on where the line sits. The status is changed to mixed.
Norway's entry described a reform as pending. Parliament voted the decriminalization bill down in June 2021 and the 2025 reform keeps the ban in place, so the status was corrected to illegal.
Peru had been recorded as legal, which was wrong. The personal-use exemption in article 299 does not name psilocybin, and the cultural-heritage declaration covers ayahuasca and nothing else, so the status was corrected to illegal.
The source this entry pointed at had gone dead, so the entry was marked for a replacement. Nothing about the law changed: Portugal's decriminalization regime under Law 30/2000 stands as it has since 2001.
Slovenia's entry was checked and its decriminalized listing held: possession for personal use is a minor offense rather than a crime.
Spain's status was confirmed at the official gazette: personal possession is not a crime, and consuming or possessing in public is an administrative infraction under article 36.16 of Ley Organica 4/2015.
St. Vincent and the Grenadines had been recorded as legal. What is described is a licensing scheme for medicinal and research use, not a general legalization, so the status was narrowed to medical.
Sweden had been recorded as decriminalized. The Narkotikastrafflag makes personal use itself a crime, so the status was corrected to illegal.
Switzerland's entry now rests on the Federal Office of Public Health's own page rather than a law firm article, and the 2024 program figures are brought up to date. The status is unchanged.
Thailand's entry was citing a narcotics act that had been repealed. It now cites the Narcotics Code of 2021 that replaced it, together with the 2024 notification allowing psilocybin only in approved medical treatment and research. The status did not change.
Ukraine's decriminalized status was confirmed: possession of a small amount is an administrative offense. The entry now cites article 44 of the Code of Administrative Offenses and article 309 of the Criminal Code, and records a 2025 health ministry proposal to open the substances to research.
The United Kingdom's status held at Class A and Schedule 1. The entry now cites GOV.UK directly, and records two things in motion: the July 2025 trial of lighter research licensing, and the psilocybin review the government asked its drugs advisory council to carry out.
Uruguay had been recorded as legal, which overstated it. Personal-use possession is exempt from liability under article 31 of Decreto-Ley 14.294, but sale and production are still crimes, so the status moves to decriminalized.
A task force report and a ballot campaign are not a law. Alaska has enacted nothing, and the entry was corrected from mixed to illegal.
Arizona's entry was missing SB 1555, a 2025 law that would let psilocybin be prescribed only if the FDA approves it first. The 2026 bills stalled and nothing new was enacted.
California's status was confirmed and its bill list updated: SB 751 was dead by May 2025, and AB 2489 was alive but held in the Assembly Appropriations suspense file in May 2026.
Checked, with no change found. About 34 healing centers were licensed at the time of this review, and a statutory trigger dated 1 Jun 2026 opens the question of whether Colorado's program should extend beyond psilocybin.
Connecticut widened its psilocybin pilot: a law signed on 4 June 2026 opened it beyond veterans and first responders to adults generally. A separate 2025 bill to decriminalize possession passed the House and died in the Senate.
Florida had been marked mixed. Nothing in the record pulls the other way: possession is a felony and the state tightened the law again in 2025, so the status is corrected to illegal. No reform moved in 2026.
Georgia's two 2026 psychedelic laws do not let anyone use psilocybin: one waits on federal approval, the other regulates clinics. The entry now reads illegal.
Hawaii moves from mixed to illegal. Everything the state has done is a study or a task force, and no access or decriminalization measure has been enacted.
Illinois had been recorded as mixed. Its only psilocybin activity is an advisory board bill and a stalled CURE Act, neither enacted, so the status moved to illegal.
Indiana had been marked mixed. The only thing the state has enacted is a research fund, which pays for studies and opens no route for patients, so the status is corrected to illegal.
Both of Iowa's psilocybin bills failed, one by veto in 2025 and one for want of a Senate vote in May 2026. With nothing enacted, the entry was corrected from mixed to illegal.
Kansas moves from mixed to illegal. Its only psilocybin bill, which depended on a future FDA approval, stalled on the House calendar and died without becoming law.
Kentucky had been recorded as mixed on the strength of a law that is about ibogaine, not psilocybin. Senate Bill 77 changes nothing for psilocybin, so the status was corrected to illegal.
Louisiana's mixed status was confirmed. SB 43, the psychedelic therapy initiative, had passed both chambers unanimously and was sitting on the governor's desk as of June 1, 2026.
Maine had been marked mixed on the strength of a decriminalization bill. LD 1034 failed its final enactment votes and died on June 10, 2025, so the status is corrected to illegal.
The only psychedelics measure Maryland has enacted extends a task force. That is not access, and the entry was corrected from mixed to illegal.
Massachusetts stays recorded as decriminalized. The list of pending bills was updated: H.4986 now consolidates two earlier bills, H.2506 and H.2532, and sits in the Health Care Financing committee unenacted.
Michigan's status held. The bill listed as pending had long since died and was replaced with HB 4686, introduced in 2025 and sitting in committee, and a source that covered only cannabis was swapped out.
Minnesota's mixed status was confirmed. HF 2906 had moved further than the entry showed, clearing a House committee in March 2026, but it was still unenacted when the biennium closed.
Mississippi's two 2026 laws leave psilocybin where it was: one funds ibogaine trials, the other takes effect only if the federal government moves first. The status is corrected from mixed to illegal.
Missouri's psilocybin bills all stopped at the study stage, and the fate of the one the House passed in April 2026 was still unresolved at the time. The entry was corrected from mixed to illegal.
Montana moves from mixed to illegal. The only activity on record is HB 955, defeated in committee in 2023, and the legislature does not sit in regular session in 2026.
Nevada had been recorded as mixed on the strength of a working group that only studies the question. With the AB 378 pilot dead at the end of the 2025 session, nothing enacted opens access, so the status moved to illegal.
Every New Hampshire reform bill of 2025 and 2026 is dead. HB 528 was tabled in June 2025, HB 1796 was killed in February 2026, and the Senate killed HB 1809 on May 5, 2026. The status is corrected from mixed to illegal.
New Jersey's hospital pilot was confirmed, and the signing date was corrected from 16 January to 20 January 2026.
New Mexico stays recorded as medical. The state has moved its target for patient access forward to December 2026, a year earlier than planned, and an equity fund has been added.
New York had been recorded as mixed because reform bills exist. None of them has had a committee vote, and a pending bill changes no law, so the status was corrected to illegal.
North Carolina had been recorded as mixed. SB 568 was a study bill and it died at the May 2025 crossover deadline, so the status moved to illegal.
Nothing enacted, no city measure, and no bill moving in the current General Assembly. Ohio's entry was corrected from mixed to illegal.
Oklahoma moves from mixed to illegal. The only psychedelics law enacted in 2026 covers ibogaine, and no psilocybin bill was enacted.
Oregon's status held. HB 4040, which widens who may be licensed as a facilitator, became law in April 2026, and the ibogaine bill HB 4110 died in committee, so neither is listed as pending any more.
Pennsylvania had been recorded as mixed. SB 1149 has never left the committee it was referred to and the older research bills are dead, so the status moved to illegal.
Rhode Island had been marked mixed. H 7756 was withdrawn at its sponsor's request on April 9, 2026 and nothing has been enacted, so the status is corrected to illegal.
South Dakota moves from mixed to illegal. HB 1099 was signed in March 2026, but its carve-out only applies once the FDA approves a psilocybin product, so it grants no access today.
Tennessee had been recorded as mixed on the basis of a law that names only ibogaine. No psilocybin legislation exists in the state, so the status was corrected to illegal.
Texas had been recorded as mixed because the state funds psychedelic research. Funding is not access, so the status moved to illegal. SB 2308's effective date was corrected to 11 June 2025, and the state announced in March 2026 that it would run the ibogaine trials itself.
Utah's entry now records HB 390 (2026), which authorizes a study of psychedelic-assisted therapy for veterans, and the effective date of the 2024 clinical authorization is corrected to May 1, 2024. The status is unchanged.
Vermont's own advisory group recommended against creating a program, and the bill that followed it never moved. The listing changed from mixed to illegal.
Virginia moves from mixed to illegal. Its two trigger laws were enacted in April 2026 but stay dormant until the FDA approves a psilocybin product, and a separate bill to create an advisory council, SB 1101, was killed in the House.
Washington's status held. The medical program bill SB 5921 got further than earlier attempts and then died in the Ways and Means committee in February 2026.
West Virginia had been recorded as mixed. SB 906 is enacted but does nothing until the FDA acts, HB 4626 was vetoed, and a third bill had been listed under the wrong number, so the status moved to illegal.
The DC entry carried the wrong law number and the wrong effective date. It is D.C. Law 23-268, effective 16 March 2021. The status itself was confirmed.
The British Virgin Islands had been recorded as legal, which the statute does not support: it schedules psilocin and its esters and makes possession an offence. The gap around unlisted fresh mushrooms is real, so the status moved to mixed.
Colorado enacted HB 26-1325, which adds an ibogaine research pilot to the state natural medicine program. It takes effect August 12, 2026.
Chile changed its drug law in May 2026. The change could expose small amounts of psilocybin to a trafficking penalty, but it depends on a new list the government has not published yet.
Tennessee's entry now records that the ibogaine HOPE Treatment Act was signed on 22 May 2026 and became Public Chapter 1119. It does not concern psilocybin, whose status is unchanged.
Oklahoma's entry now records the ibogaine Breakthrough Therapy Act as enacted rather than pending, and cites the enrolled text of the act. Psilocybin's status is unchanged.
The FDA issued three national priority vouchers to psychedelic drug programs, two of them for psilocybin. A voucher speeds up FDA review; it does not approve a drug or change its legal schedule (24 Apr 2026).
The President signed Executive Order 14401, directing the FDA and the Drug Enforcement Administration to speed up psychedelic drug review, build an early access route for seriously ill patients, and consider rescheduling once a drug finishes Phase 3 trials. As of this review the access route has not been set up (91 FR 21709).
Utah's entry now records the 2026 scheduling act that would follow a federal rescheduling of an approved psilocybin medicine, and corrects the description of the veterans research law, which authorizes a study but appropriates no money itself.
The DEA set the quantities of psilocybin and psilocyn that registered researchers and manufacturers may legally produce in the United States during 2026 (91 FR 287).
Pennsylvania's entry now records both psilocybin bills before the General Assembly, HB 1439 as well as SB 1149. Neither has moved and the legal position is unchanged.
Vermont's entry now records all three psychedelic bills before the General Assembly, and cites the statute that prohibits psilocybin rather than the advisory working group. Nothing in Vermont law has changed.
Psilocybin and psilocyn became Schedule I controlled substances when the Controlled Substances Act took effect on 1 May 1971 (21 U.S.C. 812).
Every entry here also lives on the changelog of the record it belongs to, and corrections are never silent. Dates are the date of the recorded change. For how status is verified and how corrections are handled, see the methodology.